HomeCompareFIXX vs EQR

FIXX vs EQR: Dividend Comparison 2026

FIXX yields 213.97% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FIXX wins by $177.38M in total portfolio value
10 years
FIXX
FIXX
● Live price
213.97%
Share price
$0.93
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$177.43M
Annual income
$92,441,271.48
Full FIXX calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — FIXX vs EQR

📍 FIXX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFIXXEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FIXX + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FIXX pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FIXX
Annual income on $10K today (after 15% tax)
$18,187.65/yr
After 10yr DRIP, annual income (after tax)
$78,575,080.76/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, FIXX beats the other by $78,570,426.49/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FIXX + EQR for your $10,000?

FIXX: 50%EQR: 50%
100% EQR50/50100% FIXX
Portfolio after 10yr
$88.74M
Annual income
$46,223,373.54/yr
Blended yield
52.09%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

FIXX
Analyst Ratings
5
Buy
4
Hold
Consensus: Buy
Price Target
$2.70
+188.9% upside vs current
Range: $2.70 — $2.70
Altman Z
-2.8
Piotroski
4/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FIXX buys
0
EQR buys
0
No recent congressional trades found for FIXX or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFIXXEQR
Forward yield213.97%5.87%
Annual dividend / share$2.00$3.47
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$177.43M$47.8K
Annual income after 10y$92,441,271.48$5,475.61
Total dividends collected$167.81M$23.0K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold
Analyst price target$2.70$70.35

Year-by-year: FIXX vs EQR ($10,000, DRIP)

YearFIXX PortfolioFIXX Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$32,097$21,397.24$11,380$679.82+$20.7KFIXX
2$98,530$64,186.20$13,014$837.25+$85.5KFIXX
3$289,572$184,144.93$14,961$1,036.20+$274.6KFIXX
4$815,624$505,782.06$17,297$1,289.22+$798.3KFIXX
5$2,204,131$1,331,413.21$20,121$1,613.15+$2.18MFIXX
6$5,721,029$3,362,608.71$23,561$2,030.84+$5.70MFIXX
7$14,278,479$8,156,977.31$27,783$2,573.54+$14.25MFIXX
8$34,304,224$19,026,251.97$33,013$3,284.39+$34.27MFIXX
9$79,425,902$42,720,382.43$39,547$4,223.51+$79.39MFIXX
10$177,426,987$92,441,271.48$47,791$5,475.61+$177.38MFIXX

FIXX vs EQR: Complete Analysis 2026

FIXXStock

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing for various genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, cardiac and skeletal muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II, as well as HMI-104 for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.

Full FIXX Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this FIXX vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FIXX vs SCHDFIXX vs JEPIFIXX vs OFIXX vs KOFIXX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.